Monkeypox vaccines and monoclonal antibodies
Document text
Principal Investigator: NANCY J SULLIVAN Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES Fiscal Year: 2023 Award: $18,581 Funding agency: National Institute of Allergy and Infectious Diseases In these studies, we are evaluating a vaccine against Monkeypox that utilizes an mRNA platform, which has a more favorable safety profile and scalability. Manufacturing is also scalable with a short lag time from immunogen design to production making it amenable for rapid deployment of new antigens during outbreaks.Over the last several years, the use of mRNA as vaccines has become a promising candidate that can elicit potent immune responses. mRNA vaccines were used successfully across the globe during the SARS-CoV-2 pandemic and are being developed to counter other pathogens. The mRNA is encapsulated in the lipid nanoparticles (LNPs) that have been shown to mediate efficient protein expression by transducing mRNA in vivo. mRNA LNPs are self-adjuvating, are non-infectious, express protein with high efficiency and can be administered at small doses to induce protective immune responses. Protection will be evaluated in mice and nonhuman primates. Protective antibodies will then be isolated from animal subjects for use as therapeutics. Terms: <Animals><Antibodies><Antigens><Bleb><Blister><Bulla><Bullous Lesion><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><Clinical Treatment Moab><Disease><Disease Outbreaks><Disorder><Dose><Encapsulated><Exanthem><Exanthema><Exposure to><Fever><Health><Health Care Providers><Health Personnel><Healthcare Providers><Healthcare worker><Human><Immune response><Immunize><Immunological response><Individual><Lymph Node Reticuloendothelial System><Lymph node proper><Lymphatic nodes><Mediating><Messenger RNA><Mice><Mice Mammals><Modern Man><Monkey Pox><Monkey Pox Virus><Monkeypox><Monkeypox virus><Monkeypoxvirus><Monoclonal Antibodies><Murine><Mus><Outbreaks><P variolae><P. variolae><P.variolae><Poxviridae><Poxvirus officinale><Poxvirus variolae><Poxviruses><Preventative vaccine><Preventive vaccine><Production><Prophylactic vaccine><Proteins><Pyrexia><RNA vaccine><RNA-based vaccine><Rash><Reporting><Risk><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><Safety><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severity of illness><Skin><Skin Rash><Smallpox><Smallpox Vaccine><Smallpox virus><Swelling><Symptoms><Therapeutic><Time><Vaccines><Vaccinia virus><Variola><Variola major virus><Variola virus><Vesication><Virus><Zoonoses><Zoonotic><Zoonotic Infection><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><design><designing><disease severity><febrile><febris><health care personnel><health care worker><health provider><health workforce><healthcare personnel><high risk group><high risk individual><high risk people><high risk population><host response><immune system response><immunogen><immunoresponse><in vivo><lipid based nanoparticle><lipid nanoparticle><lymph gland><lymph nodes><lymphnodes><mAbs><mRNA><mRNA vaccine><mRNA-based vaccine><manufacture><medical personnel><monoclonal Abs><mpox><mpxv><non-human primate><nonhuman primate><pathogen><pox virus><protein expression><public health emergency><recombinant vaccinia virus><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><small pox><small pox vaccine><small pox virus><treatment provider><vaccine antibodies><vaccine induced antibodies><vaccine-induced antibodies><variola major>